-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Akero Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
- Akero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$72.7M, a 83.3% decline year-over-year.
- Akero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$237M, a 98.3% decline year-over-year.
- Akero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$152M, a 35.5% decline from 2022.
- Akero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$112M, a 11.2% decline from 2021.
- Akero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$101M, a 27.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)